1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Decker GA, Batheja MJ, Collins JM, et al. Risk factors for pancreatic adenocarcinoma and prospects for screening. Gastroenterol Hepatol (N Y). 2010;6(4):246-254.
3. Dragovich T. Pancreatic cancer (2011). http://emedicine.medscape.com/article/280605 -overview#showall. Accessed February 17, 2012.
4. Stoita A, Penman ID, Williams DB. Review of screening for pancreatic cancer in high-risk individuals. World J Gastroenterol. 2011;17(19): 2365-2371.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ): Pancreatic Adenocarcinoma, Version 2.2012 (2011). www.nccn.org/profession als/physician_gls/pdf/pancreatic.pdf. Accessed March 2, 2012.
6. National Cancer Institute, US Department of Health and Human Services, NIH. Cancer Trends Progress Report, 2009/2010 Update. http://pro gressreport.cancer.gov/doc detail.asp?pid=1&did=2009&chid=95&coid=926&mid=. Accessed February 22, 2012.
7. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute. http://seer.cancer .gov/csr/1975_2008/index.html. Accessed February 17, 2012.
8. Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011;378(9791);607-620.
9. Koorstra JBM, Feldmann G, Habbe N, Maitra A. Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs). Langenbecks Arch Surg. 2008;393(4):561–570.
10. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6(8):2969-2972.
11. Lubezky N, Ben-Haim M, Lahat G, et al. Intraductal papillary mucinous neoplasm of the pancreas: associated cancers, family history, genetic predisposition? Surgery. 2012;151(1):70-75.
12. Takaori K, Hruban RH, Maitra A, Tanigawa N. Current topics on precursors to pancreatic cancer. Adv Med Sci. 2006;51:23-30.
13. Hruban RH, Fukushima N. Pancreatic adenocarcinoma: update on the surgical pathology of carcinomas of ductal origin and PanINs. Mod Pathol. 2007;20 suppl 1:S61-S70.
14. Dunphy EP. Pancreatic cancer: a review and update. Clin J Oncol Nurs. 2008:12(5):735-741.
15. Carpelan-Holström M, Nordling S, Pukkala E, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut. 2005; 54(3):385-387.
16. Magruder JT, Elahi D, Andersen DK. Diabetes and pancreatic cancer: chicken or egg? Pancreas. 2011;40(3):339-351.
17. Chari ST, Leibson CL, Rabe KG, et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005; 129(2):504-511.
18. University of Chicago Medical Center. Pancreatic cancer screening (2011). www.uchospitals .edu/specialties/cancer/pancreatic/screening.html. Accessed February 22, 2012.
19. Pezzilli R, Morselli-Labate AM, Mantovani V, et al. Mutations of the CFTR gene in pancreatic disease. Pancreas. 2003;27(4):332-336.
20. Hruban RH, Klein AP, Eshleman JR, et al. Familial pancreatic cancer: from genes to improved patient care. Expert Rev Gastroenterol Hepatol. 2007;1(1):81-88.
21. Blackford A, Parmigiani G, Kensler TW, et al. Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res. 2009; 69(8):3681-3688.
22. Lynch SM, Vrieling A, Lubin JH, et al. Cigarette smoking and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium. Am J Epidemiol. 2009;170(4):403-413.
23. Fernández-Del Castillo C, Jiminez RE. Epidemiology and risk factors for exocrine pancreatic cancer (2011). www.uptodate.com/contents/epidemi ology-and-risk-factors-for-exocrine-pancreatic-cancer. Accessed February 17, 2012.
24. Agency for Healthcare Research and Quality, US Preventive Services Task Force. Guide to Clinical Preventive Services 2010-2011: Recommendations of the US Preventive Services Task Force. www .ahrq.gov/clinic/pocketgd.htm. Accessed March 5, 2012.
25. Holly EA, Chaliha, I, Bracci PM, Gautam M. Signs and symptoms of pancreatic cancer: a population-based case-control study in the San Francisco Bay area. Clin Gastroenterol Hepatol. 2004; 2(6):510-517.
26. Garcia AA, Egner JR. Pancreatic cancer and primary care providers. Cancer Pract. 1995;3(1):37-41.
27. Shah MM, Saif MW. Pancreatic cancer and thrombosis: highlights from the 2010 ASCO Annual Meeting, Chicago, IL, June 4-8, 2010. JOP. 2010; 11(4):331-333.
28. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol. 2004; 5(11):655-663.
29. Raptis DA, Fessas C, Belasyse-Smith P, Kurzawinski TR. Clinical presentation and waiting time targets do not affect prognosis in patients with pancreatic cancer. Surgeon. 2010;8(5):239-246.
30. Fishman MB, Aronson MD. History and physical examination in adults with abdominal pain (2011). www.uptodate.com/contents/history-and-physical-examination-in-adults-with-abdominal-pain. Accessed February 17, 2012.
31. Cartwright SL, Knudson MP. Evaluation of acute abdominal pain in adults. Am Fam Physician. 2008;77(7):971-978.
32. Penner RM, Majumdar SR. Diagnostic approach to abdominal pain in adults (2011). www.uptodate.com/contents/diagnostic-approach-to-abdominal-pain-in-adults. Accessed February 22, 2012.
33. Töx U, Hackenberg R, Stelzer A, et al. Endosonographic diagnosis of solid pancreatic tumors: a retrospective analysis from a tertiary referral center. Z Gastroenterol. 2007;45(4):307-312.
34. Schattner A, Fenakel G, Malnick SD. Cholelithiasis and pancreatic cancer. A case-control study. J Clin Gastroenterol. 1997;25(4):602-604.
35. Jura N, Archer H, Bar-Saqi D. Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between. Cell Res. 2005;15(1):72-77.
36. Thomas PC, Nash GF, Aldridge MC. Pancreatic acinar cell carcinoma presenting as acute pancreatitis. HPB (Oxford). 2003;5(2):111-113.
37. Fischer CP, Pope I, Garden OJ. Mucinous cystic tumour of the pancreas presenting with acute pancreatitis. HPB (Oxford). 2001;3(4):271-273.
38. National Cancer Institute, NIH. Pancreatic Cancer Treatment (PDQ® ) (2011). www.cancer.gov/cancertopics/pdq/treatment/pancreatic/Health Professional. Accessed February 17, 2012.
39. Humphris JL, Chang DK, Johns AL, et al; NSW Pancreatic Cancer Network. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012 Jan 11 [Epub ahead of print].
40. Miura F, Takada T, Amano H, et al. Diagnosis of pancreatic cancer. HPB (Oxford). 2006;8(5): 337-342.
41. Rickes S, Unkrodt K, Neye H, et al. Differentiation of pancreatic tumours by conventional ultrasound, unenhanced and echo-enhanced power Doppler sonography. Scand J Gastroenterol. 2002;37(11):1313-1320.
42. Adamek HE, Albert J, Breer H, et al. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet. 2000;356(9225):190-193.
43. Simianu VV, Zyromski NJ, Nakeeb A, Lillemoe KD. Pancreatic cancer: progress made. Acta Oncologica. 2010;49(4):407-417.
44. Edge SB, Byrd DR, Compton CC, et al, eds; American Joint Committee on Cancer. AJCC Staging Manual. 7th ed (2011). Staging of pancreatic tumors. www.cancerstaging.org/staging/posters/pancreas8.5x11.pdf. Accessed February 17, 2012.
45. Katz MH, Hwang R, Fleming JB, Evans DB. Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin. 2008;58(2): 111-125.
46. Takahashi S, Kinoshita T, Konishi M, et al. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment. J Hepatobiliary Pancreat Sci. 2011;18(4):567-574.
47. Castellanos E, Berlin J, Cardin DB. Current treatment options for pancreatic carcinoma. Curr Oncol Rep. 2011;13(3):195-205.
48. Nguyen TC, Sohn TA, Cameron JL, et al. Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors. J Gastrointest Surg. 2003;7(1):1-9.
49. Kuvshinoff BW, Bryer MP. Treatment of resectable and locally advanced pancreatic cancer. Cancer Control. 2000;7(5):428-436.
50. Sauter PP, Coleman J. Pancreatic cancer: a continuum of care. Sem Oncol Nurs. 1999;15(1):36-47.
51. Springett GM, Hoffe SE. Borderline resectable pancreatic cancer: on the edge of survival. Cancer Control. 2008;15(4):295-307.
52. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25(15):1960-1966.
53. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27(33):5513-5518.
54. Colucci G, Labianca R, Di Costanzo F, et al; the GIP-1 study. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer. J Clin Oncol. 2010; 28(10):1645-1651.
55. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006; 24(24):3946-3952.
56. Conroy T, Desseigne F, Ychou M, et al; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-1825.
57. Pelzer U, Kubica K, Stieler J, et al. A randomized trial in patients with gemcitabine-refractory pancreatic cancer: final results of the CONKO 003 study. J Clin Oncol. 2008;26(15; May 20 suppl; abstr 4508, 2008 Annual Meeting, American Society of Clinical Oncology).
58. Xiong HQ, Varadhachary GR, Blais JC, et al. Phase ll trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008; 113(8):2046-2052.
59. Brand RE, Lerch MM, Rubinstein WS, et al. Advances in counseling and surveillance of patients at risk for pancreatic cancer. Gut. 2007; 56(10):1460-1469.